Your browser doesn't support javascript.
loading
Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment.
Liu, Yushuai; Geng, Yuanyuan; Yue, Beilei; Lo, Pui-Chi; Huang, Jing; Jin, Honglin.
Afiliação
  • Liu Y; Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Geng Y; College of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
  • Yue B; College of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
  • Lo PC; Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong, SAR China.
  • Huang J; College of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
  • Jin H; College of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Front Immunol ; 12: 832942, 2021.
Article em En | MEDLINE | ID: mdl-35111169
ABSTRACT
Cancer immunotherapy can boost the immune response of patients to eliminate tumor cells and suppress tumor metastasis and recurrence. However, immunotherapy resistance and the occurrence of severe immune-related adverse effects are clinical challenges that remain to be addressed. The tumor microenvironment plays a crucial role in the therapeutic efficacy of cancer immunotherapy. Injectable hydrogels have emerged as powerful drug delivery platforms offering good biocompatibility and biodegradability, minimal invasion, convenient synthesis, versatility, high drug-loading capacity, controlled drug release, and low toxicity. In this review, we summarize the application of injectable hydrogels as a unique platform for targeting the immunosuppressive tumor microenvironment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hospedeiro Imunocomprometido / Hidrogéis / Terapia de Alvo Molecular / Microambiente Tumoral / Neoplasias Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hospedeiro Imunocomprometido / Hidrogéis / Terapia de Alvo Molecular / Microambiente Tumoral / Neoplasias Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China